Clinical Trials Browser

Abdominal Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Genital Neoplasms, Female, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms, Urogenital Neoplasms, Vulvar Diseases, Vulvar Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Epstein-Barr Virus Infections, Papillomavirus Infections, Microsatellite Instability, Small Cell Lung Carcinoma

NCT06027879 2025-06-25

Gamma Capture

Phase 1/2 Enrolling by invitation

25 enrolled

Adenoviridae Infections, Cytomegalovirus Infections, Epstein-Barr Virus Infections

NCT05164094 2025-05-15

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

Phase 1/2 Active not recruiting

867 enrolled

Infectious Mononucleosis, Epstein-Barr Virus Infections

NCT02580539 2025-05-14

EBV-TCL-01

Phase 1/2 Completed

12 enrolled

Lymphoid

Lymphoma, Epstein-Barr Virus Infections

NCT03475212 2025-05-11

ACES

Phase 1/2 Active not recruiting

52 enrolled

Primary Immunodeficiency Diseases, Adenoviridae Infections, Cytomegalovirus Infections, Epstein-Barr Virus Infections

NCT05688241 2025-03-03

ESPECT

Phase 1/2 Not yet recruiting

10 enrolled

Epstein-Barr Virus Infections

NCT03813394 2024-11-22

2018/00947

Phase 1/2 Active not recruiting

48 enrolled

Head & Neck

Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT03769467 2024-11-14

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Phase 1/2 Terminated

12 enrolled 8 charts

Head & Neck

Nasopharyngeal Carcinoma, Carcinoma, Head and Neck Neoplasms, Stomatognathic Diseases, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Nose Neoplasms, Otorhinolaryngologic Diseases, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Pharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT03283826 2024-02-23

EMBOLD

Phase 1/2 Terminated

134 enrolled

Autoimmune Diseases, Demyelinating Diseases, Inflammation, Multiple Sclerosis, Epstein-Barr Virus Infections, Multiple Sclerosis, Chronic Progressive

NCT06075927 2023-10-10

Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT

Phase 1/2 Unknown

29 enrolled

Cytomegalovirus Infections, Epstein-Barr Virus Infections

NCT03682055 2023-08-15

Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)

Phase 1/2 Terminated

14 enrolled 13 charts

Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT04507477 2022-08-02

Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial

Phase 1/2 Unknown

10 enrolled

Epstein-Barr Virus Infections

NCT00478465 2022-05-27

Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)

Phase 1/2 Completed

30 enrolled

Fatigue, Herpes Simplex, Fatigue Syndrome, Chronic, Epstein-Barr Virus Infections

NCT02496676 2022-03-02

Magnesium Supplementation in People With XMEN Syndrome

Phase 1/2 Completed

8 enrolled 7 charts

Primary Immunodeficiency Diseases, Infections, Neoplasms, Epstein-Barr Virus Infections

NCT02227641 2020-12-14

Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation

Phase 1/2 Completed

50 enrolled

Virus Diseases, Epstein-Barr Virus Infections

NCT03159364 2019-09-19

Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections

Phase 1/2 Unknown

100 enrolled

Adenoviridae Infections, Cytomegalovirus Infections, Mycoses, Tuberculosis, Epstein-Barr Virus Infections

NCT02000817 2019-06-24

Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients

Phase 1/2 Completed

30 enrolled 21 charts

Cytokine Release Syndrome, Diabetes Mellitus, Diabetes Mellitus, Type 1, Epstein-Barr Virus Infections

NCT02229981 2017-12-07

ABC-102

Phase 1/2 Withdrawn

LymphoidSarcoma

Acquired Immunodeficiency Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Sarcoma, Kaposi, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT00711035 2016-04-26

CHALLAH

Phase 1/2 Completed

50 enrolled

Adenoviridae Infections, Epstein-Barr Virus Infections

NCT00274404 2011-10-27

Controlled Trial of Valacyclovir in Infectious Mononucleosis

Phase 1/2 Completed

20 enrolled

Infectious Mononucleosis, Epstein-Barr Virus Infections